China

R&D

Clinical trends for 2025: A year of change

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials.

News

Pressure relieved on AZ as details of Chinese probe emerge

AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.

News

Hand pointing to viewer through map of China

Trump tariffs 'would strain the pharma supply chain'

Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.

R&D

5 takeaways from JP Morgan 2025

I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech.

R&D